Gain-of-function of IDH mutations occurs most frequently in low-grade glioma, cartilaginous tumors, intrahepatic cholangiocarcinoma, and certain hematological malignancies; and thus, the accumulation of D-2-HG occurs in these tumors [6]. The gene discussed is IDH1; the disease is central nervous system cancer.